What Next for Aptose Biosciences Incorporated (NASDAQ:APTO) Stock After Decrease in Shorted Shares?

October 13, 2017 - By Jacob Falcon

 What Next for Aptose Biosciences Incorporated (NASDAQ:APTO) Stock After Decrease in Shorted Shares?

The stock of Aptose Biosciences Incorporated (NASDAQ:APTO) registered a decrease of 7.06% in short interest. APTO’s total short interest was 947,600 shares in October as published by FINRA. Its down 7.06% from 1.02 million shares, reported previously. With 148,400 shares average volume, it will take short sellers 6 days to cover their APTO’s short positions. The short interest to Aptose Biosciences Incorporated’s float is 6.02%.

The stock decreased 0.71% or $0.01 on October 13, reaching $1.39. About 127,953 shares traded. Aptose Biosciences Inc (NASDAQ:APTO) has declined 60.81% since October 13, 2016 and is downtrending. It has underperformed by 77.51% the S&P500.

Aptose Biosciences Inc. is a clinical-stage biotechnology company. The company has market cap of $33.06 million. The Firm is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. It currently has negative earnings. The Company’s product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities.

Aptose Biosciences Inc (NASDAQ:APTO) Ratings Coverage

Among 4 analysts covering Aptose Biosciences (NASDAQ:APTO), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. Aptose Biosciences had 11 analyst reports since August 7, 2015 according to SRatingsIntel. Roth Capital downgraded Aptose Biosciences Inc (NASDAQ:APTO) on Friday, November 20 to “Neutral” rating. As per Wednesday, November 16, the company rating was maintained by RBC Capital Markets. The firm has “Hold” rating by Zacks given on Friday, August 7. The firm has “Outperform” rating given on Wednesday, November 11 by RBC Capital Markets. The firm has “Neutral” rating given on Friday, November 20 by TH Capital. The company was maintained on Wednesday, August 9 by H.C. Wainwright. The firm has “Buy” rating by H.C. Wainwright given on Thursday, September 7. The stock of Aptose Biosciences Inc (NASDAQ:APTO) has “Hold” rating given on Thursday, June 8 by H.C. Wainwright. Roth Capital upgraded Aptose Biosciences Inc (NASDAQ:APTO) rating on Monday, June 13. Roth Capital has “Buy” rating and $8 target.

More notable recent Aptose Biosciences Inc (NASDAQ:APTO) news were published by: Globenewswire.com which released: “Aptose Biosciences Provides Update on APTO-253 Development” on December 29, 2016, also Seekingalpha.com with their article: “Aptose Looking Toward Human Studies” published on September 20, 2017, Seekingalpha.com published: “Aptose Remains In Limbo” on November 04, 2016. More interesting news about Aptose Biosciences Inc (NASDAQ:APTO) were released by: Globenewswire.com and their article: “Aptose Prioritizes Development of CG’806 First-in Class FLT3/BTK Inhibitor” published on January 23, 2017 as well as Seekingalpha.com‘s news article titled: “Aptose Biosciences’ (APTO) CEO William Rice on Q2 2017 Results – Earnings Call …” with publication date: August 12, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.